Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla.

Abstract

An animal model of otitis media using chinchillas was developed to evaluate the efficacy of tebipenem pivoxil (TBM-PI) against experimental otitis media. Chinchillas inoculated via the transbullar approach with Streptococcus pneumoniae serogroup 6 were included in the efficacy study with TBM-PI, amoxicillin (AMX) or untreated as controls. TBM-PI resulted in survival rate of 83%, compared with 25% survival for AMX and 0% survival for controls (p<0.01). Quantitative cultures in the middle ear effusions at day 5 of the TBM-PI group yielded 3.5+/-2.4log(10)CFUs/ml. TBM-PI is a promising antibiotic for the treatment of acute otitis media.

• Authors: Muneki Hotomi, Masaki Suzumoto, Koju Itahashi, Jun Nagura, Takayoshi Fukushima, Jun Shimada, Dewan S Billal, Kazuma Yamauchi, Keiji Fujihara, Noboru Yamanaka
• Journal: Vaccine (Vaccine) Vol. 25 Issue 13 Pg. 2478-84 (Mar 22 2007) ISSN: 0264-410X [Print] Netherlands
• PMID: 17055132 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Amoxicillin
• tebipenem

Topics

• Administration, Oral
• Amoxicillin (pharmacokinetics, pharmacology)
• Animals
• Anti-Bacterial Agents (pharmacokinetics, pharmacology)
• Carbapenems (pharmacokinetics, pharmacology)
• Chinchilla
• Male
• Models, Animal
• Otitis Media (drug therapy, metabolism, microbiology)
• Penicillin Resistance
• Pneumococcal Infections (drug therapy, metabolism)
• Streptococcus pneumoniae (isolation & purification)